Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.

18. mai 2022 oppdatert av: Universitaire Ziekenhuizen KU Leuven

Biodistribution and Dosimetry in Human Healthy Volunteers of the Novel PET Radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, Designed for Quantification of Cerebral Aggregated Mutant Huntingtin in Huntington's Disease.

A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.

[11C]CHDI-00485180-R and [11C]CHDI-00485626 are two novel mutant huntingtin aggregate binding PET radioligands which have already demonstrated sensitivity to mutant huntingtin load in animal models. In the current study, the biodistribution and dosimetry of both these ligands will be investigated in young healthy volunteers according to a standard approach, in 3 subjects (including both genders) per tracer.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

For both groups, the dynamic whole-body distribution of the respective tracer labelled with [11C] will be measured after IV administration of 370 MBq. Two venous catheters, one on each arm, will be used for : 1/ the injection of [11C]CHDI-00485180-R or [11C]CHDI-00485626 tracer solution and 2/ for venous blood sampling (blood biochemistry and metabolites).

All images will be acquired using the SIEMENS Truepoint Biograph 40 PET-CT scanner. First, a CT scout will be acquired to set the axial field of view (FOV). The axial FOV should extend from the top of the head to the middle of the thighs (approximately 6-7 bed positions). Then, a low dose CT will be acquired for enabling PET attenuation correction and anatomical information (organ delineation). Following the CT, 10 sets of WB 3D PET images in total will be acquired sequentially. The first set of 9 whole body PET scans (scan segment 1) will be acquired, starting at the time of injecting [11C]CHDI-00485180-R solution or [11C]CHDI-00485626 solution. After this sequence of PET acquisitions, which will take up to 100 min, the subject will be moved out of the scanner and will be encouraged to void the bladder. After a 30 minute break, the subject will be repositioned in the PET/CT scanner and a second low dose CT will be acquired. WB scan 10 (scan segment 2) will be started at 2 hours after [11C]CHDI-00485180-R or [11C]CHDI-00485626 injection, scanning for a total scan duration of about 28 minutes.

During the first WB PET/CT scan segment, 6 venous blood samples (4 mL each) per subject will be taken at 5, 10, 20, 40, 60 and 100 min after [11C]CHDI-00485180-R or [11C]CHDI-00485626 injection. This will allow testing and further optimization of the HPLC metabolite analysis for future brain imaging studies with full kinetic modelling and quantification.

Studietype

Observasjonsmessig

Registrering (Faktiske)

6

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Belgia
      • Leuven, Belgia, 3000
        • UZ Leuven

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

6 young (18-55 years), healthy subjects, 3 for panel A ([11C]CHDI-00485180-R) and 3 for panel B [(11C]CHDI-00485626). Each panel should include both genders (i.e., 2M/1F or 2F/1M).

Beskrivelse

Inclusion Criteria:

  • Male or female subjects, age between 18 and 55 years old
  • Subject is judged to be in good health by the investigator on the basis of medical history. When still in doubt, a full physical and neurological examination can be conducted

Exclusion Criteria:

  • Subject has a history of major internal disease that may interfere with the investigations (especially liver and kidney disease, cancer or uncontrolled diabetes).
  • Subject has any history of a major neurological or psychiatric disorder
  • Subject is currently smoker (> 20 cigarettes or equivalent/day) a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
  • Subject has had exposure to ionizing radiation (> 1 mSv) in other research studies within the last 12 months.
  • Subject suffers from claustrophobia or cannot tolerate confinement during PET-CT scanning procedures; subject cannot lie still for 90 minutes inside the scanner.
  • Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity (i.e. weight lifting, running, bicycling) 3 days before and during the day of scanning.
  • Subject does not understand the study procedure
  • Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator.
  • Subject is potentially pregnant (hCG will be performed in women with childbearing potential).
  • Allergy for local anesthesia (lidocaine)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
[11C]CHDI-180R
Biodistribution and whole-body dosimetry for [11C]CHDI-00485180-R in 3 healthy volunteers.
Annen: [11C]CHDI-00485180-R
Mutant huntingtin aggregate binding PET radioligand.
[11C]CHDI-626
Biodistribution and whole-body dosimetry for [11C]CHDI-00485626 in 3 healthy volunteers.
Annen: [11C]CHDI-00485626
Mutant huntingtin aggregate binding PET radioligand.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Normalized cumulated activity coefficients (NCA)
Tidsramme: Single point measure - during the acquisition of the PET scan (+- 2 hours 30minutes)
Normalized cumulated activity coefficients (MBq-hr/hr) for indicated source organs determined from whole-body imaging.
Single point measure - during the acquisition of the PET scan (+- 2 hours 30minutes)
Total organ doses
Tidsramme: Single point measure - during the acquisition of the PET scan (+- 2 hours 30minutes)
Total organ doses (µGy/MBq) for indicated target organs.
Single point measure - during the acquisition of the PET scan (+- 2 hours 30minutes)
Effective doses (ED)
Tidsramme: Single point measure - during the acquisition of the PET scan (+- 2 hours 30minutes)
Effective doses (µSv/MBq) for indicated target organs.
Single point measure - during the acquisition of the PET scan (+- 2 hours 30minutes)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Universitaire Ziekenhuizen KU Leuven

Samarbeidspartnere

CHDI Foundation, Inc.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juli 2020

Primær fullføring (Faktiske)

13. oktober 2020

Studiet fullført (Faktiske)

13. oktober 2020

Datoer for studieregistrering

Først innsendt

13. januar 2022

Først innsendt som oppfylte QC-kriteriene

24. januar 2022

Først lagt ut (Faktiske)

4. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. mai 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. mai 2022

Sist bekreftet

1. mai 2022

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • s64086

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere